1 / 27

Recent Developments in the Treatment of Advanced and Metastatic RCC

Explore recent developments in the treatment of advanced and metastatic RCC, including results from CheckMate-214, KEYNOTE-426, JAVELIN, and IMmotion-151 trials. Learn about implications for patients with different risk profiles, biomarkers, and second-line therapy options.

whitted
Download Presentation

Recent Developments in the Treatment of Advanced and Metastatic RCC

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Recent Developments in the Treatment of Advanced and Metastatic RCC

  2. Introduction

  3. CheckMate-214: Nivolumab + Ipilimumab

  4. CheckMate-214: Results for Patients With Intermediate/Poor-Risk Disease[a,b]

  5. CheckMate-214: Results for Patients With Favorable-Risk Disease

  6. How Do You Treat?

  7. Nivolumab/Ipilimumab in Patients With Disease With Sarcomatoid Features

  8. Approval of Nivolumab/Ipilimumab in Europe

  9. Checkpoint Inhibition + VEGF Inhibition

  10. KEYNOTE-426: Pembrolizumab + Axitinib

  11. KEYNOTE-426: Results

  12. Pembrolizumab + Axitinib in Patients With Disease With Sarcomatoid Features

  13. JAVELIN Renal 101: Avelumab + Axitinib

  14. JAVELIN Renal 101: Results

  15. IMmotion 151: Atezolizumab + Bevacizumab

  16. Ongoing Phase 3 Trials in the First Line for Patients With Advanced RCC

  17. Implications of These Results for Patients With Favorable-Risk Disease

  18. Implications of These Results for Patients With Intermediate/Poor-Risk Disease

  19. Complete Response Rate

  20. Debulking Nephrectomy

  21. Debulking Nephrectomy (cont)

  22. Biomarkers

  23. Second-Line Therapy

  24. Concluding Remarks

  25. Abbreviations

  26. Abbreviations (cont)

More Related